Article
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Molecular cancer therapeutics - 1 May 2014
Gu Lei, Talati Pooja, Vogiatzi Paraskevi, Romero-Weaver Ana L, Abdulghani Junaid, Liao Zhiyong, Leiby Benjamin, Hoang David T, Mirtti Tuomas, Alanen Kalle, Zinda Michael, Huszar Dennis, Nevalainen Marja T
Abstract excerpt
Metastatic prostate cancer is lethal and lacks effective strategies for prevention or treatment, requiring novel therapeutic approaches. Interleukin-6 (IL-6) is a cytokine that has been linked with prostate cancer pathogenesis by multiple studies. However, the direct functional roles of IL-6 in prostate cancer growth and progression have been unclear. In the present study, we show that IL-6 is produced in distant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
